Get Premium to unlock powerful stock data
Calithera Biosciences Inc logo

Calithera Biosciences Inc

$ 0.21 +0.0159 (+8.07%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 20.71M
Enterprise V:
$ -21.25M
Volume:
2.71M
Avg Vol (2M):
4.49M
Also Trade In:
Volume:
2.71M
Market Cap $:
20.71M
PE Ratio:
At Loss
Avg Vol (2-Month):
4.49M
Enterprise Value $:
-21.25M
PB Ratio:
0
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Calithera Biosciences Inc
NAICS : 325412 SIC : 2834
343 Oyster Point Boulevard, Suite 200, South San Francisco, CA, USA, 94080
Description
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the US. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its lead product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Name Current Vs Industry Vs History
Cash-To-Debt 16.5
Equity-to-Asset -0.06
Debt-to-Equity -0.86
Debt-to-EBITDA -0.05
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -19.92
Distress
Grey
Safe
Beneish M-Score -3.99
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 53.64
9-Day RSI 47.44
14-Day RSI 43.78
6-1 Month Momentum % -72.24
12-1 Month Momentum % -88.88

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.16
Quick Ratio 4.16
Cash Ratio 3.93
Days Sales Outstanding 11.03

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -25.7
Name Current Vs Industry Vs History
Operating Margin % -590.94
Net Margin % -1113.11
ROE % -211.28
ROA % -131.24
ROIC % -1028.32
ROC (Joel Greenblatt) % -1743.22
ROCE % -82.71

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.61
EV-to-EBIT 0.37
EV-to-EBITDA 0.37
EV-to-Revenue -2.18
EV-to-FCF 0.35
Earnings Yield (Greenblatt) % 270.27

Financials (Next Earnings Date:2022-08-05 Est.)

CALA's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CALA

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 9.75
EPS (TTM) ($) -1.44
Beta 1.49
Volatility % 72.63
14-Day RSI 43.78
14-Day ATR ($) 0.032111
20-Day SMA ($) 0.214825
12-1 Month Momentum % -88.88
52-Week Range ($) 0.15445 - 2.5927
Shares Outstanding (Mil) 97.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Calithera Biosciences Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More